The Danish firm claims its ingredient, which is produced by fermentation, is a natural, high purity product that is highly efficacious at very low doses.
The company said it uses mushroom mycelia as a source material, which is fermented using sugar. This enables the delivery of active beta glucans, in which the molecular structure has been protected from damage often caused by chemical process steps such as solvent extraction, it said.
“The intact structure of Fluxome’s beta glucans allows for a very high immune enhancing effect, which has been demonstrated to be superior to that of products made by traditional extraction processes.”
The fermentation process also ensures a consistent quality product, said Fluxome.
Low dose, high efficacy
According to Mads Bjornhof, marketing manager at the firm, the recommended daily dose of its beta glucan is 1mg per day. This is delivered via 1g per day of the product blend, which is pre-formulated and ready to be used in tablet or capsule applications.
The low-dose, high-efficacy combination makes the ingredient competitively priced compared to other products on the market, Bjornhof told NutraIngredients-USA.com.
Fluxome and its Norwegian partner corporation GlycaNova, which manufacturers the product, say the new efficacy and safety of the beta glucan have been clinically proven in four human clinical trials and several in vitro and animal studies. None of the trials have as yet been published.
Bjornhof said the ingredient has been self-affirmed GRAS (generally recognized as safe), but Fluxome’s initial focus will be to target dietary supplement applications “because we believe there is great potential there”.
Although no official health claims are associated with the ingredient, Fluxome is marketing it as “enabling the enhancement of the immune system”.